Change Bio provides an end‑to‑end platform that turns designed protein sequences into manufacturable strains and bioreactor‑scale protein samples. Their nsure service creates expressing *K. phaffii* strains within a week and enables high‑throughput library screening, while the rapid prototyping service delivers fed‑batch fermented protein samples that reflect industrial conditions, generating data to predict large‑scale manufacturability. Successful proteins can be licensed with the full strain‑construction, fermentation, and data infrastructure to scale production directly to commercial volumes.
Funding
$200K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Protein engineers face slow, low‑throughput strain construction in *K. phaffii* and prototyping services that produce samples at small, non‑representative scales, making it difficult to predict manufacturability and accelerate design‑build‑test cycles.
Solution
Change Bio offers an end‑to‑end platform that makes designed proteins manufacturable at bioreactor scale. The nsure service converts amino‑acid sequences into expressing strains within a week and enables library construction and screening of hundreds to thousands of variants, eliminating the bottleneck of single‑sequence workflows. Its rapid prototyping service returns usable protein samples produced by fed‑batch fermentation under industrially representative conditions in weeks, providing data that predicts large‑scale manufacturability. For proteins that succeed, Change Bio licenses the nsure platform, strain‑construction methods, fermentation processes, and data infrastructure, allowing partners to scale production directly from prototype to commercial volume.
Target Audience
Primary customers are protein engineering teams and biotech companies developing novel proteins for cosmetics, food, and advanced materials who need fast, scalable manufacturing data and a path to industrial production.
Features
- nsure platform delivers sequence‑to‑expressing strain in as little as one week, supporting high‑throughput library construction in *K. phaffii*.
- Capability to screen hundreds to thousands of sequences per run, far exceeding traditional one‑by‑one workflows.
- Rapid prototyping service produces protein samples via fed‑batch fermentation at bioreactor scale, mirroring commercial production conditions.
- Generates manufacturability data (expression levels, process performance) alongside protein samples to inform scale‑up decisions.
- Licensing model provides full access to strain‑construction protocols, fermentation processes, and data infrastructure for industrial production.
- Supports both per‑protein projects and reserved‑capacity multi‑iteration cycles for continuous design‑build‑test workflows.